ATE253645T1 - Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien - Google Patents

Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien

Info

Publication number
ATE253645T1
ATE253645T1 AT93909210T AT93909210T ATE253645T1 AT E253645 T1 ATE253645 T1 AT E253645T1 AT 93909210 T AT93909210 T AT 93909210T AT 93909210 T AT93909210 T AT 93909210T AT E253645 T1 ATE253645 T1 AT E253645T1
Authority
AT
Austria
Prior art keywords
nucleic acids
stool samples
reagents required
required therefor
mammal nucleic
Prior art date
Application number
AT93909210T
Other languages
English (en)
Inventor
Bert Vogelstein
Kenneth W Kinzler
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE253645T1 publication Critical patent/ATE253645T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
AT93909210T 1992-04-01 1993-03-31 Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien ATE253645T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86191092A 1992-04-01 1992-04-01
PCT/US1993/002960 WO1993020235A1 (en) 1992-04-01 1993-03-31 Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor

Publications (1)

Publication Number Publication Date
ATE253645T1 true ATE253645T1 (de) 2003-11-15

Family

ID=25337083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93909210T ATE253645T1 (de) 1992-04-01 1993-03-31 Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien

Country Status (8)

Country Link
US (2) US5910407A (de)
EP (1) EP0672181B1 (de)
JP (1) JP3633932B2 (de)
AT (1) ATE253645T1 (de)
CA (1) CA2132874C (de)
DE (1) DE69333289T2 (de)
ES (1) ES2210239T3 (de)
WO (1) WO1993020235A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US6235470B1 (en) 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
ATE247176T1 (de) * 1994-12-29 2003-08-15 Eiken Chemical Verfahren zur zellerkennung
DE19530132C2 (de) * 1995-08-16 1998-07-16 Max Planck Gesellschaft Verfahren zur Reinigung, Stabilisierung oder Isolierung von Nukleinsäuren aus biologischen Materialien
GB9518156D0 (en) * 1995-09-06 1995-11-08 Medical Res Council Method of isolating cells
NO954667D0 (no) 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
US6448002B1 (en) * 1996-08-26 2002-09-10 Invitek Gmbh Method to detect clinically relevant mutations of the DNA sequence of ki-ras oncogene, its use and a testkit for early diagnosis of tumors
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
EP0939118A1 (de) * 1998-02-20 1999-09-01 Universiteit Maastricht Verfahren zur Isolierung von DNA und RNA aus Stuhlproben
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
EP1155147B1 (de) * 1999-02-25 2006-06-14 EXACT Sciences Corporation Verfahren zur erhaltung der dns-integrität
JP4794052B2 (ja) 1999-04-09 2011-10-12 ジェンザイム・コーポレーション 癌の指標である核酸を検出するための方法
JP2003530817A (ja) 1999-06-01 2003-10-21 ベイラー カレッジ オブ メディスン 聴覚障害、変形性関節症および細胞の異常増殖に関するatonal関連配列の治療用途のための組成物および方法
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US7368233B2 (en) 1999-12-07 2008-05-06 Exact Sciences Corporation Methods of screening for lung neoplasm based on stool samples containing a nucleic acid marker indicative of a neoplasm
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
DE50113146D1 (de) 2000-02-04 2007-11-29 Qiagen Gmbh Nukleinsäure-isolierung aus stuhlproben und anderen biologischen materialien, die reich an inhibitoren sind
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
AU758744B2 (en) * 2000-10-31 2003-03-27 F. Hoffmann-La Roche Ag Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US20030165940A1 (en) 2001-12-06 2003-09-04 The Johns Hopkins University Disease detection by digital protein truncation assays
EP1572902B1 (de) 2002-02-01 2014-06-11 Life Technologies Corporation HOCHWIRKSAME siRNAS ZUR REDUZIERUNG DER EXPRESSION VON ZIELGENEN
WO2003064625A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20060258856A1 (en) * 2002-02-13 2006-11-16 Medimolecular Pty. Ltd. Method of isolating nucleic acids from stool samples
WO2003071252A2 (en) 2002-02-15 2003-08-28 Exact Sciences Corporation Methods for analysis of molecular events
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
EP2269618A1 (de) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Ein onkolytisches Vaccinia-Virus zur Verwendung in Kombination mit Chemotherapie zur Behandlung von Krebs
US20090305294A1 (en) * 2003-02-13 2009-12-10 Medimolecular Pty Ltd Method of isolating nucleic acids from stool samples
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
US7189068B2 (en) * 2003-09-19 2007-03-13 Gast Manufacturing, Inc. Sound reduced rotary vane compressor
WO2005111244A2 (en) * 2004-05-10 2005-11-24 Exact Sciences Corporation Methods for detecting a mutant nucleic acid
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
US7981607B2 (en) * 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
EP1802775B1 (de) 2004-09-14 2010-05-26 The Regents of the University of Colorado Auf genetischem targeting basierendes verfahren zur behandlung mit bucindolol
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
JP2006166711A (ja) * 2004-12-13 2006-06-29 Okayama Univ 糞便由来遺伝子の簡便増幅方法
WO2007044071A2 (en) 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
AU2006261671A1 (en) * 2005-06-27 2007-01-04 John Wayne Cancer Institute Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
EP1933857A2 (de) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemische behandlung von metastasierten und/oder systemisch dissemierten tumoren mit gm-csf-exprimierenden pockenviren
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
JP2010533714A (ja) * 2007-07-16 2010-10-28 ポニアード ファーマシューティカルズ, インコーポレイテッド ピコプラチンのための経口製剤
AU2009210656A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
CN102105583A (zh) * 2008-07-23 2011-06-22 奥林巴斯株式会社 从粪便试样中回收核酸的方法、核酸分析方法以及粪便试样处理装置
EP2789689B1 (de) 2009-06-29 2016-04-27 Luminex Corporation Chimäre Primer mit Haarnadel-Konformationen und Verfahren zur Verwendung davon
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
WO2011032180A1 (en) 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
US9045729B2 (en) 2009-12-10 2015-06-02 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US20130131161A1 (en) 2009-12-23 2013-05-23 Michael R. Bristow Methods and compositions for cardiovascular diseases and conditions
EP2661278B1 (de) 2011-01-04 2019-06-19 SillaJen Biotherapeutics, Inc. Tumorspezifischen komplementabhängigen zytotoxizität (cdc) antikörper erzeugert durch verabreichung von onkolytischen vacciniaviren, zur behandlung von krebs
MX2013009863A (es) 2011-02-28 2013-12-06 Univ Iowa Res Found Cambios de la hormona anti-mulleriana en el embarazo y prediccion de sexo y de resultados adversos en el embarazo.
AU2012226530B2 (en) 2011-03-08 2016-12-01 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
GB201107466D0 (en) 2011-05-05 2011-06-15 Loktionov Alexandre Device and method for non-invasive collection of colorectal mucocellular layer and disease detection
WO2012167382A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
AU2012273121B2 (en) 2011-06-19 2016-08-25 Abogen, Inc. Devices, solutions and methods for sample collection
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
MX2016004283A (es) 2013-10-03 2016-10-12 Oklahoma Med Res Found Biomarcadores para la actividad, e intesidad y arrebato de la enfermedad lupus eritematoso sistemico.
SG11201607364RA (en) 2014-03-07 2016-10-28 Dna Genotek Inc Composition and method for stabilizing nucleic acids in biological samples
US20180057839A1 (en) 2014-11-26 2018-03-01 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
AU2018213315A1 (en) 2017-01-26 2019-07-25 Oklahoma Medical Research Foundation Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US12140592B2 (en) 2017-06-16 2024-11-12 Oklahoma Medical Research Foundation Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
EP3810182A4 (de) 2018-06-19 2022-08-24 BioNTech US Inc. Neoantigene und ihre verwendungen
US12510539B2 (en) 2018-10-18 2025-12-30 Progentec Diagnostics, Inc. Biomarkers for a systemic lupus erythematosus (SLE) disease activity immune index that characterizes disease activity
EP3867645B1 (de) 2018-10-18 2024-06-05 Oklahoma Medical Research Foundation Biomarker für krankheitsaktivitätimmunindex von systemischem lupus erythematodes (sle) zur charakterisierung der krankheitsaktivität
EP3874273B1 (de) 2018-10-31 2024-03-27 Arizona Board of Regents on behalf of the University of Arizona Biomarker und verfahren zur verwendung bei strahlungsinduzierter lungenverletzung
JP2022547627A (ja) 2019-09-16 2022-11-14 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Swi-snf変異型腫瘍の処置のための組成物および方法
CN113186185B (zh) * 2020-01-14 2023-05-26 东北林业大学 一种从哺乳动物粪便中高效富集宿主dna的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US5482834A (en) * 1982-05-17 1996-01-09 Hahnemann University Evaluation of nucleic acids in a biological sample hybridization in a solution of chaotrophic salt solubilized cells
US5037959A (en) * 1984-05-29 1991-08-06 Lubrizol Genetics, Inc. Self incompatibility protein
FR2567541B1 (fr) 1984-07-13 1987-02-06 Pasteur Institut Sonde d'adn et procede pour la detection de " shigelles " et des souches entero-invasives de escherichia coli
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5053331A (en) * 1986-04-21 1991-10-01 Lubrizol Genetics, Inc. Self-incompatibility gene
US4935342A (en) * 1986-12-01 1990-06-19 Syngene, Inc. Method of isolating and purifying nucleic acids from biological samples
US5024934A (en) 1988-03-14 1991-06-18 The Board Of Regents, The University Of Texas System Detection of minimal numbers of neoplastic cells carrying DNA translocations by DNA sequence amplification
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
AU7224591A (en) 1990-01-24 1991-08-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A rapid and sensitive test for detecting hepatitis a virus
US5352775A (en) * 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
US5330892A (en) * 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5612473A (en) * 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification

Also Published As

Publication number Publication date
JPH08504081A (ja) 1996-05-07
US5910407A (en) 1999-06-08
DE69333289T2 (de) 2004-08-26
US6177251B1 (en) 2001-01-23
EP0672181B1 (de) 2003-11-05
EP0672181A4 (de) 1997-03-26
EP0672181A1 (de) 1995-09-20
JP3633932B2 (ja) 2005-03-30
CA2132874A1 (en) 1993-10-14
WO1993020235A1 (en) 1993-10-14
CA2132874C (en) 2003-08-19
DE69333289D1 (de) 2003-12-11
ES2210239T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
ATE253645T1 (de) Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien
ATE204381T1 (de) Verfahren zur quantifizierung von biologischem material in einer probe
DE68907407D1 (de) Verfahren zur sequenzanalyse von dna.
FI950487A7 (fi) Menetelmä, reagenssi ja testipakkaus nukleiinihapposekvenssien totamis eksi ja monistamiseksi
DE69328622D1 (de) Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben
ATE232559T1 (de) Verfahren zur signalverstärkung
DE69634696D1 (de) Verfahren und testsystem zur hybridisierungsanalyse unter verwendung von peptidnukleinsäure-sonden
ATE557103T1 (de) Verfahren zur erkennung von nukleinsäuresequenzen in urin
ATE267878T1 (de) Die bestimmung von nukleinsäuremutationen durch analyse des sputum
ATE141651T1 (de) Verfahren zum nachweis und zur identifizierung von nukleinsäure enthaltenden teilen
ATE230801T1 (de) Verfahren zur detektion von zielnukleinsäure, verfahren zu ihrer quantifizierung und pyrylium- verbindungen zur chemilumineszenz-analyse
DE69808740D1 (de) Verfahren und kit zur quantifizierung und nukleinsäuresequenzierung von nukleinsäureanalyten in einer probe
ATE172500T1 (de) Verfahren und reagenzien zur bestimmung von bakterien in der zerebrospinalen flüssigkeit
DE3854056D1 (de) Verfahren zum Nachweis einer Nukleinsäure-Sequenz in einer Probe.
DE3887168D1 (de) Verfahren zur quantitativen analyse von mineralien.
DE3853254D1 (de) Ausrüstungssatz und Verfahren für Analysen von biologischen Proben.
DE69113960D1 (de) ATR-Objektiv und Verfahren zur Probenuntersuchung.
DE69918123D1 (de) Verfahren und reagentiensatz zur erkennung von protein-protein wechselwirkungen
DE3863285D1 (de) Verfahren und reagenz zur bestimmung von persaeuren.
FI950507A7 (fi) Määritysmenetelmä proteiinin määrittämiseksi biologisesta näytteestä
ATE111533T1 (de) Verfahren zur bestimmung von nukleinsäuren.
DE59609198D1 (de) Verfahren und Reagenz zur spezifischen Bestimmung von LDL in Serumproben
DE69319752D1 (de) Verfahren zur identifizierung von analyten
ATE354800T1 (de) Verfahren zum nachweiss von antikörpern in einer probe
DE69119399D1 (de) Reagens und verfahren für serum eisenproben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties